PETV PetVivo Holdings, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1512922 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.5%
TTM net income YoY0.2%
TTM EPS YoY18.9%
Revenue 3-yr CAGR4.4%
Net income 3-yr CAGR—
Margins
Gross margin70.3%
Operating margin-796.7%
Net margin-798.7%
FCF margin-386.1%
EBITDA margin-769.4%
Returns
ROE-433.2%
ROA-235.4%
ROIC (approx.)-424.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio0.31x
Interest coverage-394.93x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-122.2%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.14M | $1.13M |
| Cost of revenue | $386,856 | $137,677 |
| Gross profit | $754,751 | $994,856 |
| R&D expense | $1.42M | $1.58M |
| SG&A expense | $4.33M | $4.82M |
| Operating income | -$9.06M | -$8.06M |
| Interest expense | $12,667 | $6,138 |
| Pretax income | -$10.47M | -$8.40M |
| Net income | -$10.47M | -$8.40M |
| EBITDA | -$8.55M | -$7.88M |
| EPS (basic) | -0.38 | -0.41 |
| EPS (diluted) | -0.38 | -0.41 |
| Weighted avg. shares (diluted) | 30.15M | 20.49M |
| Banking | ||
| Net interest income | — | -$359,408 |
| Balance sheet | ||
| Cash & equivalents | $200,782 | $227,689 |
| Short-term investments | $150,000 | $150,000 |
| Receivables | $100,843 | $60,573 |
| Inventory | $538,366 | $323,504 |
| Current assets | $1.71M | $5.61M |
| PP&E, net | $448,881 | $766,874 |
| Intangibles | $20,509 | $23,725 |
| Total assets | $3.58M | $9.34M |
| Current liabilities | $1.38M | $4.32M |
| Total liabilities | $1.38M | $5.12M |
| Shareholders' equity | $2.20M | $4.22M |
| Shares outstanding | 35.85M | 24.18M |
| Cash flow statement | ||
| Operating cash flow | -$6.11M | -$5.32M |
| Capital expenditure | $7,734 | $63,434 |
| Free cash flow | -$6.12M | -$5.39M |
| Investing cash flow | $11,800 | -$563,434 |
| Financing cash flow | $6.07M | $6.03M |
| Depreciation & amortization | $511,457 | $174,590 |
| Stock-based compensation | $1.88M | $1.11M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.